STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088088
Completed
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2008
Locations: NEA Clinic, Jonesboro, Arkansas +18 locations
Conditions: Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Register for Updates
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
NCT00669747
Unknown
The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion. Secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/01/2008
Locations: OU Medical Center Laboratory, Oklahoma City, Oklahoma +1 locations
Conditions: Ductal Carcinoma In Situ
Register for Updates
Phase II CT-2103/Carboplatin in Ovarian Cancer
NCT00069901
Completed
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2008
Locations: California Cancer Care, Greenbrae, California +16 locations
Conditions: Ovarian Neoplasm
Register for Updates
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
NCT00161278
Terminated
Patients who are at least 18 years of age and have a type of cancer known as advanced non-small cell lung cancer may be eligible for this study if they meet all of the inclusion/exclusion criteria. Background: The standard treatment for patients with advanced non-small cell cancer is chemotherapy. The two drug combination, carboplatin (Paraplatin) and paclitaxel (Taxol), is commonly used as the first treatment. Unfortunately, standard treatment with chemotherapy only shrinks the cancer in about... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2008
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Advanced Non-Small Cell Lung Cancer
Register for Updates
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
NCT00025688
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Highlands Oncology Group, Springdale, Arkansas +24 locations
Conditions: Breast Cancer
Register for Updates
Therapy for Children With Neuroblastoma
NCT00135135
Completed
This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy, intensification with autologous stem cell transplantation, and an oral maintenance phase with 13-cis-retinoic acid and topotecan. We hypothesize that the ZD1839 (gefitinib) and irinotecan window will be efficacious.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
06/02/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
Large Cell Lymphoma Pilot Study III
NCT00187070
Completed
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with hematopoietic stem cell support for children with large cell lymphoma
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/06/2008
Locations: St. Jude Children's Reaearch Hospital, Memphis, Tennessee
Conditions: Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Register for Updates
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
NCT00001502
Completed
The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with preclinical and clinical antitumor activity against a... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Brain Neoplasms, Glioma, Medulloblastoma
Register for Updates
SU5416 and Carboplatin to Treat Ovarian Cancer
NCT00006155
Completed
SU5416, a novel antiangiogenesis agent, has been shown to be a potent and selective inhibitor of the tyrosine kinase activity of FlK-1 (a downstream effector of VEGF) in vitro and to inhibit the growth of endothelial cells. Since VEGF mRNA levels and vessel counts in tumor tissues have been shown to be inversely related to prognosis in ovarian cancer, SU5416 may prove to be a useful agent in this disease. Platinum agents currently provide the most effective treatment for ovarian cancer. However,... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Fallopian Tube Neoplasm, Ovarian Cancer, Peritoneal Neoplasm
Register for Updates
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
NCT00148135
Terminated
This study is for patients with a type of cancer called carcinoma of unknown primary site (CUP), meaning that the site of the body where the tumor has originated is not clear. Currently, carcinoma of unknown primary site (CUP) accounts for about 5% of all newly diagnosed malignancies. The stage of the tumor is such that it is not treatable by surgery. Currently, the standard treatment for such a type of cancer at that stage is chemotherapy. However, the overall prognosis for patients with metast... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/28/2007
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Carcinoma of Unknown Primary
Register for Updates
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer
NCT00578149
Completed
This study is being done to learn what effects (good and bad) bevacizumab in conjunction with carboplatin/paclitaxel and radiation therapy has on patients with non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2007
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer
NCT00190710
Completed
To determine and compare the median survival produced by combined Gemcitabine plus Paraplatin versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2007
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas
Conditions: Non-Small Cell Lung Cancer
Register for Updates